Adults aged 85 years and older, the “oldest old,” are the fastest‐growing age group in the
United States, yet relatively little is known about their cancer burden. Combining data from …

Introduction The risk of polypharmacy is on the rise in most industrialized countries,
threatening to burden their health systems. Although many definitions exist and numerous …

Most patients diagnosed with luminal metastatic breast cancer (MBC) who are seen in
oncology consultations are elderly. MBC in elderly patients is characterized by a higher …

Introduction Cancer incidence, comorbidity, and polypharmacy increase with age, but the
interplay between these factors on receipt of systemic therapy (ST) in advanced cancer has …

Background There is no nationwide data on polypharmacy in palliative care in Japan. In this
study, the research committee of the Japanese Society for Pharmaceutical Palliative Care …

Background: Gastrointestinal malignancies represent a particularly challenging condition,
often requiring a multidisciplinary approach to management in order to meet the unique …

Introduction Optimizing the approach to older adults with cancer is now a priority given the
increasing frequency of new cancer diagnoses that are made in the older population. The …

The median number of medications taken by adults aged 65 and older is four, but may be
higher in older adults with cancer. A high number of prescribed medications increases risk …

Introduction Polypharmacy increases hazard of drug-drug interactions (DDIs),
hospitalization, treatment toxicity, and mortality in elderly individuals with cancer. The …

Introduction Polypharmacy is prevalent among cancer patients; however, its relationship
with comorbidities as well as its other potential factors has not been well studied among this …